Literature DB >> 23928241

Breast magnetic resonance imaging for screening high-risk women.

Janice S Sung1, D David Dershaw.   

Abstract

Mammography is the only imaging modality that has been validated by multiple randomized clinical trials and meta-analyses to reduce mortality from breast cancer. Although it is demonstrated to be effective in reducing mortality from breast cancer, mammography has its limitations, especially in young high-risk women with dense breasts. Other imaging modalities have been pursued as an adjunct screening modality in this population. Of these, the most widely accepted is contrast-enhanced breast magnetic resonance (MR) imaging. This article reviews current recommendations and limitations of using MR imaging of the breast to screen asymptomatic women at high risk for breast cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRCA; Cancer; Genetic; Hodgkin; Lymphoma; Risk

Mesh:

Substances:

Year:  2013        PMID: 23928241     DOI: 10.1016/j.mric.2013.02.006

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  8 in total

Review 1.  Imaging Surveillance After Primary Breast Cancer Treatment.

Authors:  Diana L Lam; Nehmat Houssami; Janie M Lee
Journal:  AJR Am J Roentgenol       Date:  2017-01-11       Impact factor: 3.959

2.  Quantitative evaluation of redox ratio and collagen characteristics during breast cancer chemotherapy using two-photon intrinsic imaging.

Authors:  Shulian Wu; Yudian Huang; Qinggong Tang; Zhifang Li; Hannah Horng; Jiatian Li; Zaihua Wu; Yu Chen; Hui Li
Journal:  Biomed Opt Express       Date:  2018-02-28       Impact factor: 3.732

3.  Concordance of BI-RADS Assessments and Management Recommendations for Breast MRI in Community Practice.

Authors:  Amie Y Lee; Laura Ichikawa; Janie M Lee; Christoph I Lee; Wendy B DeMartini; Bonnie N Joe; Karen J Wernli; Brian L Sprague; Sally D Herschorn; Constance D Lehman
Journal:  AJR Am J Roentgenol       Date:  2016-01       Impact factor: 3.959

Review 4.  Breast Cancer Screening for High-Risk Patients of Different Ages and Risk - Which Modality Is Most Effective?

Authors:  Elizabeth Wellings; Lauren Vassiliades; Reem Abdalla
Journal:  Cureus       Date:  2016-12-28

5.  Predictive performance of BI-RADS magnetic resonance imaging descriptors in the context of suspicious (category 4) findings.

Authors:  João Ricardo Maltez de Almeida; André Boechat Gomes; Thomas Pitangueiras Barros; Paulo Eduardo Fahel; Mário de Seixas Rocha
Journal:  Radiol Bras       Date:  2016 May-Jun

6.  Associating Automated Breast Ultrasound (ABUS) and Digital Breast Tomosynthesis (DBT) with Full-Field Digital Mammography (FFDM) in Clinical Practice in Cases of Women with Dense Breast Tissue.

Authors:  Ioana Boca Bene; Anca Ileana Ciurea; Ștefan Cristian Vesa; Cristiana Augusta Ciortea; Sorin Marian Dudea; Simona Manole
Journal:  Diagnostics (Basel)       Date:  2022-02-11

7.  Breast cancer screening: updated recommendations of the Brazilian College of Radiology and Diagnostic Imaging, Brazilian Breast Disease Society, and Brazilian Federation of Gynecological and Obstetrical Associations.

Authors:  Linei Augusta Brolini Dellê Urban; Luciano Fernandes Chala; Selma di Pace Bauab; Marcela Brisighelli Schaefer; Radiá Pereira Dos Santos; Norma Medicis de Albuquerque Maranhão; Ana Lucia Kefalas; José Michel Kalaf; Carlos Alberto Pecci Ferreira; Ellyete de Oliveira Canella; João Emílio Peixoto; Heverton Leal Ernesto de Amorim; Helio Sebastião Amâncio de Camargo Junior
Journal:  Radiol Bras       Date:  2017 Jul-Aug

8.  Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: A systematic review and meta-analysis.

Authors:  Matteo Basilio Suter; Filippo Pesapane; Giorgio Maria Agazzi; Tania Gagliardi; Olga Nigro; Anna Bozzini; Francesca Priolo; Silvia Penco; Enrico Cassano; Claudio Chini; Alessandro Squizzato
Journal:  Breast       Date:  2020-06-10       Impact factor: 4.380

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.